Jiuzhitang (000989)'s 2020 semi-annual board of directors operating review contains the following content: 1. Overview In the first half of 2020, the COVID-19 epidemic swept the world, causing an unprecedented impact on countries and industries around the world. It also had an impact on the development of the pharmaceutical industry.
Positive effect.
In the fight against the epidemic, traditional Chinese medicine has played an important role. Many traditional Chinese medicines have been officially included in diagnosis and treatment plans at all levels. Clinical efficacy observations show that the total effectiveness of traditional Chinese medicine in the prevention and control of this epidemic has reached more than 90%.
.
The significant role of traditional Chinese medicine in fighting the epidemic is conducive to enhancing the strategic position and social recognition of traditional Chinese medicine in the country, and is conducive to promoting the internationalization process of traditional Chinese medicine.
At the same time, the government's concept of "from treating diseases to preventing diseases" will also lead national health consumption to a more mature stage, and the big health industry will usher in major development opportunities.
On the other hand, the reform of the medical system continues to deepen, the consistency evaluation of injections has been launched, the national centralized drug procurement has been normalized, the medical security system, the drug management system and other pharmaceutical policies have been intensively introduced. The pharmaceutical industry will still be in the adjustment stage, and industry competition will
Further intensified, industry concentration continues to increase.
In the face of challenges and opportunities, while inheriting the theory, culture and medical technology of traditional Chinese medicine, the company is guided by people's health needs in the new era, adheres to the development concept of "combination of inheritance and innovation", and practices the "Century-old Jiuzhitang, serving the world"
With the mission of "health", we integrate traditional medicine and modern medicine, lay out the business of stem cell medicine industry and medicinal and food homologous series products. At the same time, in compliance with the country's policy guidance of vigorously developing Internet medical care, we will explore and advance based on "Internet + Traditional Chinese Medicine"
The Internet hospital project has been put into trial operation one after another. It is committed to providing accurate and effective services for human health management throughout the life cycle from the three fields of prevention, treatment and rehabilitation, and creating a healthy and beautiful life for mankind.
During the reporting period, the company "cultivated new opportunities in crises and opened new opportunities in changes", strengthened cultural confidence, strategic confidence, and path confidence, deepened the group's management and control model, continued to cultivate the core advantages of traditional businesses, and rapidly promoted the steady development of innovative businesses.
Focusing on the annual business work plan, we actively carry out various tasks, and the overall production and operation status is good.
In terms of production, the company adheres to normalized management of epidemic prevention and control, and its epidemic prevention and control capabilities and production management capabilities continue to improve. The company's overall production and epidemic prevention and control are safe and stable, and all employees are free of infection. In terms of operations, the company gives full play to the locomotive role of the market to
Sales work is the core, tapping the potential of existing varieties to ensure that traditional products are better and stronger; in terms of innovation, the company is intensively cultivating and in-depth layout of the stem cell business, following the trend to explore new business models on the Internet, and accelerating the development direction of health products with the same source of medicine and food.
, actively promote breakthroughs in innovative projects and ensure the company's sustainable development in the future.
In the first half of 2020, the company achieved operating income of 1,832.9736 million yuan, a year-on-year increase of 8.55%, and net profit attributable to shareholders of listed companies of 197.115 million yuan, a year-on-year increase of 11.71%.
During the reporting period, the company mainly carried out the following work: 1. Actively promote the re-evaluation of products on the market and improve product competitiveness 1.1 Youbo Pharmaceutical Shuxuetong Injection evidence-based medicine and re-evaluation project During the reporting period, the "Twelve
The "Five" major special project Shuxuetong Injection Evidence-Based Medicine Clinical Research (SPACE) research group held a symposium. The test results showed that Shuxuetong Injection has a definite anti-thrombotic effect in identifying people with high-risk factors for embolism. Clinical trials
The plan has been published in SCI articles; at the "12th Healthy China Forum Evidence-Based Traditional Chinese Medicine Parallel Forum" sponsored by People's Daily, People's Daily Health Client, and Health Times, Shuxuetong Injection was selected by the Evidence-Based Traditional Chinese Medicine Research Alliance
Ranked first in the "Top 10 Evidence-Based Evaluation Index of Chinese Patent Medicines (Stroke)". This is the first authoritative evaluation of the clinical value of Chinese patent medicine products from the perspective of evidence-based medicine. According to the clinical evidence index analysis method of Chinese patent medicines, it is based on clinical research.
Evaluation based on the quantity, quality and expert knowledge can fully reflect the comprehensive strength of the clinical effectiveness evidence of proprietary Chinese medicines.
During the reporting period, the company's proactive re-evaluation of Shuxuetong Injection progressed steadily.
Experiments related to the safety re-evaluation of Shuxuetong Injection continue to be carried out, and the group labels of leech and earthworm medicinal materials have passed the project review of the Standardization Office of the Chinese Society of Chinese Medicine; relying on the "Research on the Material Basis and Action Mechanism of Shuxuetong Injection" carried out by Tianjin University of Traditional Chinese Medicine
"The project has published 6 academic articles and applied for 8 patents.
This work laid a solid foundation for continuously improving the clinical value of the company's leading product Shuxuetong Injection and effectively carrying out professional academic promotion.
1.2 Siqi Bio Siqikang standard improvement project During the reporting period, the company’s BCG polysaccharide nucleic acid injection (Siqikang) standard improvement project completed the isolation, purification, component analysis and sequencing of nucleic acid components, and nucleic acid immunization
Factor TNF-α stimulation experiments, polysaccharide chemical structure analysis, efficacy tests, etc. have laid the foundation for rational explanation of the material basis and mechanism of action of Siqikang and the establishment of highly specific quality standards.